While the use of interferon for pRCC evidently yields poor oncologic outcome, its use for advanced pRCC should be further explored as should the use of interferon before VEGF therapies which is being explored for ccRCC [38] since black patients may be more likely to experience an oncologic benefit. The gene discussed is VEGFA; the disease is nonpapillary renal cell carcinoma.